Table 2.
Baseline characteristics of patients after PSM.
| Variable | Tirofiban (n = 68) | Non-tirofiban (n = 68) | P-value |
|---|---|---|---|
| Age, median (IQR) | 62 (54–70) | 62 (53–69) | 0.984 |
| Male sex, n (%) | 43 (63.2) | 44 (64.7) | 1.000 |
| Initial NIHSS score, median (IQR) | 15 (12–19) | 15 (10–19) | 0.877 |
| Medical history | |||
| Atrial fibrillation, n (%) | 22 (32.4) | 26 (38.2) | 0.591 |
| Hypertension, n (%) | 36 (52.9) | 25 (36.8) | 0.084 |
| Diabetes mellitus, n (%) | 13 (19.1) | 9 (13.2) | 0.486 |
| Hypercholesterolemia, n (%) | 5 (7.4) | 5 (7.4) | 1.000 |
| Ischemic stroke, n (%) | 9 (13.2) | 12 (17.7) | 0.636 |
| Smoking, n (%) | 26 (38.2) | 28 (41.2) | 0.861 |
| Prior antiplatelet use, n (%) | 7 (10.3) | 8 (11.8) | 1.000 |
| Prior anticoagulant use, n (%) | 0 (0.0) | 1 (1.5) | 1.000 |
| Pre-stroke mRS score, n (%) | 1.000 | ||
| 0 | 66 (97.1) | 65 (95.6) | |
| 1 | 2 (2.9) | 3 (4.4) | |
| Stroke causative mechanism, n (%) | 0.608 | ||
| Large artery atherosclerosis | 32 (47.1) | 30 (44.1) | |
| Cardioembolism | 27 (39.7) | 32 (47.1) | |
| Other | 9 (13.2) | 6 (8.8) | |
| ASPECTS, median (IQR) | 10 (8–10) | 10 (8–10) | 0.802 |
| Treatment profiles | |||
| General anesthesia, n (%) | 19 (27.9) | 22 (32.3) | 0.709 |
| Number of pass, median (IQR) | 3 (2–4) | 2 (1–3) | 0.169 |
| Heparin during MT, n (%) | 24 (35.3) | 27 (39.7) | 0.723 |
| IA thrombolysis, n (%) | 3 (4.4) | 2 (2.9) | 1.000 |
| Permanent stenting, n (%) | 14 (20.6) | 9 (13.2) | 0.361 |
| Transfer from primary stroke center, n (%) | 21 (30.9) | 26 (38.2) | 0.471 |
| OPT time, median (IQR), min | 253 (208–301) | 255 (215–293) | 0.969 |
| PRT time, median (IQR), min | 80 (53–130) | 81 (52–117) | 0.686 |
ASPECTS, Alberta Stroke Program Early CT Score; IA, intraarterial; IQR, interquartile range; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale; OPT, onset-to-puncture time; and PRT, puncture-to-recanalization time.